Tag: central nervous system

January 24, 2019

Seelos Therapeutics Announces Successful Completion of its Merger with Apricus Biosciences

Seelos Therapeutics (Nasdaq:SEEL), a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical...
November 29, 2018

VistaGen Therapeutics Receives Hong Kong Patent for Methods of Production for AV-101

VistaGen Therapeutics (NASDAQ:VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with...
October 3, 2018

VistaGen Therapeutics Receives FDA Fast Track Designation for Development of AV-101 as a Non-Opioid Treatment for Neuropathic Pain

VistaGen Therapeutics (NASDAQ:VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with...
September 28, 2018

Intra-Cellular Therapies Completes Submission of New Drug Application for Lumateperone for Treatment of Schizophrenia

Intra-Cellular Therapies (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced...
July 30, 2018

Apricus Biosciences Announces Merger Agreement with Seelos Therapeutics

Apricus Biosciences (NASDAQ:APRI) has announced it has signed an agreement to merge with Seelos Therapeutics in an all-stock transaction. As...
May 13, 2018

5 Top Weekly NASDAQ Biotech Stocks: Helius Up 43.19 Percent

Helius Medical Technologies, vTv Therapeutics, Second Sight Medical Products, Depomed and Senomyx were last week's top gainers on the NASDAQ.
May 9, 2018

Supernus Announces First Quarter 2018 Financial Results and Record Quarterly Revenue

Supernus Pharmaceuticals (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system...